Overcoming Healthcare’s catch-22: How to ditch these five risky habits
https://blogs.cisco.com/healthcare/overcoming-healthcares-catch-22-how-to-ditch-these-five-risky-habits
HIMSS Analytics Developing a New Standard for Measuring Hospital Infrastructure Adoption
https://blogs.cisco.com/healthcare/himss-analytics-developing-a-new-standard-for-measuring-hospital-infrastructure-adoption
Ask a cybersecurity expert: What are the top 4 tips for securing health data?
https://blogs.cisco.com/healthcare/ask-a-cybersecurity-expert-what-are-the-4-top-tips
The Wait is Almost Over: HIMSS Analytics INFRAM Provides a Roadmap to Infrastructure Maturity
https://blogs.cisco.com/healthcare/the-wait-is-almost-over-himss-analytics-infram-provides-a-roadmap-to-infrastructure-maturity
It’s Here: HIMSS Analytics INFRAM Now Available for Healthcare Organizations
https://blogs.cisco.com/healthcare/its-here-himss-analytics-infram-now-available-for-healthcare-organizations
Bladder Cancer Risk Higher With Radiation Therapy for Prostate Cancer
https://www.cancertherapyadvisor.com/bladder-cancer-higher-risk-for-prostate-surgery-treatment-risk/article/806723/
Native Puerto Ricans Are at Increased Risk for Certain Cancers
https://www.cancertherapyadvisor.com/native-puerto-ricans-higher-cancer-risk/article/806546/
Radiotherapy Did Not Improve Survival in All Patients With Metastatic Prostate Cancer
https://www.cancertherapyadvisor.com/radiotherapy-did-not-improve-survival-in-all-patients-with-metastatic-prostate-cancer/article/810701/
Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer
https://www.cancertherapyadvisor.com/breast-cancer-atezolizumab-nab-paclitaxel-prolongs-survival-treatment/article/808965/
Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
https://www.cancertherapyadvisor.com/trastuzumab-duration-lowers-cost-breast-cancer-uk-study-effective/article/809064/
Recent Comments